Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

Tonix’s Sept. 10, 2026 fireside chat with CEO Seth Lederman will be live webcast, with a replay available on the company’s website.

Rhea-AI Summary

Tonix Pharmaceuticals (TNXP) will participate in Cantor’s 2026 Global Healthcare Conference in New York, where management will host a fireside chat and 1x1 meetings with investors.

The fireside chat, presented by President and CEO Seth Lederman, M.D., is scheduled for September 10, 2026, from 3:55–4:25 p.m. ET. A live webcast and replay will be accessible under the News & Events tab in the Investors section of the Tonix website. Tonix is a commercial-stage biopharmaceutical company focused on CNS disorders, infectious diseases, immunology, and rare diseases. Its marketed portfolio includes TONMYA for fibromyalgia and acute migraine products Zembrace SymTouch and Tosymra, alongside a pipeline of Phase 2 and vaccine candidates in multiple therapeutic areas.

Argus Sep 2 session 5 alerts

-4.22% close to close 1.1x rel. volume Open Argus

Details

Market move: TNXP -4.22% in the Sep 2 session. 2026 healthcare conference

$230.17M Market Cap

On Sep 2, the day this news came out, TNXP closed 4.22% below the previous close. Our momentum scanner recorded 5 alerts for this stock that day.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

1x1 Meetings: 1x1s Conference Dates: September 9-11, 2026 Presentation Date: September 10, 2026 +5 more

1x1 Meetings

1x1s

Cantor's 2026 Global Healthcare Conference

Conference Dates

September 9-11, 2026

Cantor's 2026 Global Healthcare Conference

Presentation Date

September 10, 2026

Cantor fireside chat

Presentation Time

3:55-4:25 p.m. ET

Cantor fireside chat

TONMYA Dosage

2.8 mg

Cyclobenzaprine HCl sublingual tablets

Zembrace SymTouch Dosage

3 mg

Sumatriptan injection

Tosymra Dosage

10 mg

Sumatriptan nasal spray

Pipeline Development Stage

Phase 2

TONMYA studies and multiple development programs

Historical Context

5 past events · Latest: Aug 10

5 events

1. Aug 10

   Second-quarter earnings

   24h Move

   +4.7%

   Revenue growth and commercialization progress drove the second-quarter update.

2. Aug 05

   Investor conference participation

   24h Move

   +0.5%

   Management announced participation in two upcoming investor conferences.

3. Aug 03

   FDA meeting update

   24h Move

   +6.5%

   FDA minutes showed alignment on the planned adaptive Phase 2 study.

4. Jul 27

   Earnings date announcement

   24h Move

   +5.0%

   The company scheduled its second-quarter financial results and operational update.

5. Jul 15

   Preclinical publication

   24h Move

   +5.0%

   Peer-reviewed publication reported comparative mpox virulence findings in animal models.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cns, monoclonal antibody, phase 2, investigational new drugs

4 terms

cns medical

"focused on central nervous system (CNS) disorders"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

monoclonal antibody medical

"including monoclonal antibody, Phase 2 ready TNX-4800"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

phase 2 medical

"Tonix is extending the science behind TONMYA in Phase 2 clinical studies"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

investigational new drugs regulatory

"are investigational new drugs or biologics"

Investigational new drugs are medicines that are being tested in people but have not yet been approved for general use by health authorities. They matter to investors because clinical trial results and regulatory decisions determine whether these prototypes become sellable products—success can unlock large future revenues, while failures or delays can sharply reduce a company’s expected value, much like a prototype that may or may not make it to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor’s 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York.

Cantor’s 2026 Global Healthcare Conference
Fireside Chat
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: September 10, 2026
Presentation Time: 3:55-4:25 p.m. ET

A live webcast and replay will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical need. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® SymTouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody, Phase 2 ready TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA^® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Deborah Elson (Investors/Media)
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
investor.relations@tonixpharma.com

Brian Korb (Investors)
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Andrea Cohen (Media)
Sam Brown Inc.
(917) 209-7163
andreacohen@sambrown.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tonix Pharmaceuticals (TNXP) present at Cantor’s 2026 Global Healthcare Conference?

Tonix Pharmaceuticals is scheduled to present a fireside chat at Cantor’s 2026 Global Healthcare Conference on September 10, 2026, from 3:55–4:25 p.m. ET, as part of the New York event running September 9–11, 2026.

Who will represent Tonix Pharmaceuticals (TNXP) at Cantor’s 2026 Global Healthcare Conference fireside chat?

The fireside chat for Tonix Pharmaceuticals at Cantor’s 2026 Global Healthcare Conference will be presented by Seth Lederman, M.D., who serves as the company’s President and Chief Executive Officer.

How can investors watch Tonix Pharmaceuticals’ Cantor 2026 conference presentation (TNXP)?

A live webcast and replay of Tonix Pharmaceuticals’ fireside chat at Cantor’s 2026 Global Healthcare Conference will be available under the News & Events tab in the Investors section of the company’s website at https://ir.tonixpharma.com/.

What therapeutic areas does Tonix Pharmaceuticals (TNXP) focus on as highlighted in the Cantor 2026 notice?

Tonix Pharmaceuticals focuses on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical need, supported by both marketed products and a pipeline of investigational candidates.

What are the key marketed products of Tonix Pharmaceuticals (TNXP) mentioned in the conference announcement?

Tonix’s key marketed products include TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg) for fibromyalgia and acute migraine therapies Zembrace SymTouch (sumatriptan injection 3 mg) and Tosymra (sumatriptan nasal spray 10 mg). These are supported by the company’s CNS commercial infrastructure.

Which clinical pipeline programs of Tonix Pharmaceuticals (TNXP) are referenced in the Cantor conference update?

The update references Phase 2 studies of TONMYA in major depressive disorder and acute stress disorder/reaction, infectious disease candidates TNX-4800 for Lyme disease prevention and TNX-801 for mpox/smallpox, immunology candidate TNX-1500 for kidney transplant rejection prevention, and rare disease candidate TNX-2900 for Prader-Willi syndrome.